Bluebird claims EU nod for rare disease therapy SkysonaBluebird bio has its first approval for Skysona (formerly Lenti-D), its gene therapy for children with the rare Share XBluebird claims EU nod for rare disease therapy Skysonahttps://pharmaphorum.com/news/bluebird-claims-eu-nod-for-rare-disease-therapy-skysona/
EMA starts review of latecomer GSK/Sanofi COVID-19 vaccineThe EMA has kicked off a rolling review of a COVID-19 vaccine from Sanofi and GlaxoSmithKline, which started Share XEMA starts review of latecomer GSK/Sanofi COVID-19 vaccinehttps://pharmaphorum.com/news/ema-starts-review-of-latecomer-gsk-sanofi-covid-19-vaccine/
Another hurdle down as EU clears AstraZeneca’s Alexion takeoverThe European Commission has given competition clearance to the $39 billion acquisition of Alexion by AstraZeneca, leaving the Share XAnother hurdle down as EU clears AstraZeneca’s Alexion takeoverhttps://pharmaphorum.com/news/another-hurdle-down-as-eu-clears-astrazenecas-alexion-takeover/
Keytruda beats Opdivo to first-line oesophageal cancer OK in EuropeMerck & Co’s Keytruda has become the first cancer immunotherapy to be approved as a first-line oesophageal cancer Share XKeytruda beats Opdivo to first-line oesophageal cancer OK in Europehttps://pharmaphorum.com/news/keytruda-beats-opdivo-to-first-line-oesophageal-cancer-ok-in-europe/
Libtayo gets a double with EU approvals in skin, lung cancerSanofi and Regeneron’s checkpoint inhibitor Libtayo has tripled its approved uses in Europe, after getting the nod for Share XLibtayo gets a double with EU approvals in skin, lung cancerhttps://pharmaphorum.com/news/libtayo-gets-a-double-with-eu-approvals-in-skin-lung-cancer/
AZ, MSD’s Koselugo is first EU therapy for neurofibromatosisThe European Commission has approved AstraZeneca and MSD’s Koselugo for a rare genetic condition that causes tumours to Share XAZ, MSD’s Koselugo is first EU therapy for neurofibromatosishttps://pharmaphorum.com/news/az-msds-koselugo-is-first-eu-therapy-for-neurofibromatosis/
After FDA rejection, EU says yes to Sanofi’s Aubagio in kids with MSSanofi’s Aubagio has become the first oral therapy approved for first-line use in children and adolescents with multiple Share XAfter FDA rejection, EU says yes to Sanofi’s Aubagio in kids with MShttps://pharmaphorum.com/news/after-fda-rejection-eu-says-yes-to-sanofis-aubagio-in-children/
EU okays BMS’ azacitidine pill for first-line maintenance of AMLBristol-Myers Squibb has been granted EU approval for Onureg (azacitidine), a tablet form of an intravenous drug that Share XEU okays BMS’ azacitidine pill for first-line maintenance of AMLhttps://pharmaphorum.com/news/eu-okays-bms-azacitidine-pill-for-first-line-maintenance-of-aml/
EU and AZ both claim victory in COVID jab supply lawsuitA court in Belgium has ordered AstraZeneca to deliver additional doses of its COVID-19 vaccine to EU member Share XEU and AZ both claim victory in COVID jab supply lawsuithttps://pharmaphorum.com/news/eu-and-az-both-claim-victory-in-covid-jab-supply-lawsuit/
